Note 16 Geographic and Product Data

The Company markets and sells its products in more than 75 countries and conducts its manufacturing in the United States. Other than the Japan, China, the United States, and Korea, the Company does not conduct business in any country in which its sales in that country exceed 10% of consolidated net sales. Sales are attributed to countries based on location of customers. The composition of the Company’s sales to unaffiliated customers is set forth below (in thousands):

Net sales to unaffiliated customers	2017		2016		2015
Japan	$	17,424	$	17,329	$	16,982
China		23,881		16,019		12,571
United States		7,894		9,859		10,904
Korea		5,543		7,455		8,061
Others*		35,869		31,770		28,605
Total	$	90,611	$	82,432	$	77,123

*No other location individually exceeds 10% of total sales.

100% of the Company’s sales are generated from the ophthalmic surgical product segment and the chief operating decision maker makes the operating decisions and allocates resources based upon the consolidated operating results, therefore, the Company operates as one operating segment for financial reporting purposes. The Company’s principal products are IOLs used in cataract surgery and ICLs used in refractive surgery. The composition of the Company’s net sales by product line is as follows (in thousands):

Net sales by product line	2017		2016		2015
ICLs	$	68,325	$	59,111	$	51,543
IOLs		17,258		19,706		19,857
Other surgical products		5,028		3,615		5,723
Total	$	90,611	$	82,432	$	77,123

The composition of the Company’s long-lived assets, consisting of property and equipment, net, and intangible assets, net, between those in the United States, Switzerland, and Japan is set forth below (in thousands):

Long-lived assets	2017		2016
U.S.	$	8,523	$	10,704
Switzerland		912		737
Japan		612		822
Total	$	10,047	$	12,263

The Company sells its products internationally, which subjects the Company to several potential risks, including fluctuating exchange rates (to the extent the Company’s transactions are not in U.S. dollars), regulation of fund transfers by foreign governments, United States and foreign export and import duties and tariffs, and political instability.

Historical Timeline

Fiscal Year	Filed
2017	Feb 28, 2018	Showing above
2016	Mar 2, 2017

About Segments Disclosures

Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.

Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.

STAAR SURGICAL CO Segments Disclosure

Historical Timeline

About Segments Disclosures

Other Available Disclosures